Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioSTU:TGK 51 OCF Margin % is 0.95% as of Mar. 2026. GuruFocus rates STU:TGK with a GF Score™ of 51/100 and a GF Value™ of €2.26. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Precipio ranks worse than 52.22% on this metric.
The historical rank and industry rank for Precipio's OCF Margin % or its related term are showing as below:
STU:TGK'
s OCF Margin % Range Over the Past 10 Years
Min: -388.28 Med: -78.18 Max: 2.85
Current: 3.08
During the past 13 years, the highest OCF Margin % of Precipio was 2.85%. The lowest was -388.28%. And the median was -78.18%.
STU:TGK's OCF Margin % is ranked worse than 52.22% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.84
vs STU:TGK: 3.08
Precipio OCF Margin % Related Terms
Precipio OCF Margin % Historical Data
* Premium members only.
The historical data trend for Precipio's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:TGK vs QUCY, IDXG, BIOQ: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Precipio's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Precipio's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio (STU:TGK) has a OCF Margin % of 0.95% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Precipio and its competitors. According to the industry distribution chart, Precipio ranks #106 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 52.2%.
Is Precipio's OCF Margin % too high?
Precipio's current OCF Margin % is 0.95%. The Medical Diagnostics & Research industry median OCF Margin % is 4.84. Precipio's value of 0.95% is 80.4% below this industry median. Based on the distribution chart, Precipio ranks #106 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Precipio has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Precipio's OCF Margin % compare to QUCY and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #106 out of 203 companies for OCF Margin %. This places Precipio in the lower half of its industry. The industry median OCF Margin % is 4.84. Precipio's value of 0.95% is 80.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.84, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precipio's current OCF Margin % of 0.95% is 80.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Precipio and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current OCF Margin % is 0.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Precipio (STU:TGK) has a current OCF Margin % of 0.95%. The stock's GF Value™ is €2.26, compared to a current price of €4.96 — trading 119.5% above its estimated fair value. The current OCF Margin % is 0.95% and 80.4% below the Medical Diagnostics & Research industry median of 4.84. Precipio's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Precipio (STU:TGK), the current OCF Margin % is 0.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (STU:TGK) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.
Key valuation signals for STU:TGK:
OCF Margin %: 0.95%
GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
Industry Position: 80.4% below the Medical Diagnostics & Research median (#106 of 203)
No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for STU:TGK
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TGK has been successfully added to your 
